Replies to post #1058 on Resverlogix Corp. (RVXCF)

[big orange]

My concern is that there will need to be further phase three studies on the secondary end points. Listened to the archived October 31 presentation. Appears that a lot of promising information is to be presented at the AHA meeting with no FDA approval.